KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Non Operating Income (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Other Non Operating Income data on record, last reported at -$45.1 million in Q4 2025.

  • For Q4 2025, Other Non Operating Income changed N/A year-over-year to -$45.1 million; the TTM value through Dec 2025 reached -$31.4 million, down 578.6%, while the annual FY2025 figure was -$31.4 million, N/A changed from the prior year.
  • Other Non Operating Income reached -$45.1 million in Q4 2025 per AMRX's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $31.4 million in Q4 2022 and bottomed at -$45.1 million in Q4 2025.
  • Average Other Non Operating Income over 5 years is -$575157.9, with a median of $794000.0 recorded in 2021.
  • Peak YoY movement for Other Non Operating Income: crashed 492.99% in 2021, then soared 3251.15% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at -$8.7 million in 2021, then surged by 461.01% to $31.4 million in 2022, then crashed by 92.71% to $2.3 million in 2023, then plummeted by 468.53% to -$8.4 million in 2024, then plummeted by 434.9% to -$45.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were -$45.1 million in Q4 2025, $1.2 million in Q3 2025, and $8.3 million in Q2 2025.